CM
ELVN icon

Caption Management’s Enliven Therapeutics ELVN Stock Holding History

Caption Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-72,500
Closed -$661K – 1385
2022
Q3 		$661K Buy
+72,500
New +$428K 0.01% 1001

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Caption Management's ELVN Position: Q2 2026 in Review

Caption Management sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 370,000 shares — an estimated $15.7M sold.

Caption Management first reported a position in ELVN in Q3 2022 and held it in 2 quarters. The position peaked at $14.5M in Q1 2026. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Caption Management reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 370,000 Enliven Therapeutics shares in Q2 2026, an estimated $15.7M.
  • Caption Management first reported a position in Enliven Therapeutics in Q3 2022 and held it in 2 quarters.
  • Caption Management's Enliven Therapeutics position peaked at $14.5M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.